Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection.
about
CMV in Hematopoietic Stem Cell TransplantationCord Blood as a Source of Natural Killer CellsCytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy.Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen.Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemiaThe allogeneic graft-versus-cancer effect.Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation.The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation.Impact of early CMV reactivation in cord blood stem cell recipients in the current era.Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.How Do Donor-Recipient CMV Serostatus and Post-Hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children.Characteristics and influencing factors of CD19+ B cell reconstitution in patients following haploidentical/mismatched hematopoietic stem cell transplantation.Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation.Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.
P2860
Q26740385-06C438FB-7567-4121-AAA2-5030A2CDA637Q26771337-AD0CE705-2293-4612-9AD5-54D9655A24DAQ35917480-835F5014-5610-4500-9294-4A6D0CB61C9DQ36841211-728EC2EB-F4F2-400A-82F3-90B0FDEE686AQ36920445-A1DDE8D0-3C4E-430B-B0F8-F5F890C5E917Q36966726-1FE823D1-021F-42BE-92D3-F903FDAA65FEQ37086251-495B120A-12E8-47E4-ACAA-9728171AEDD6Q37098861-7D541CA0-ED5B-4627-86AD-2D54593A4911Q37593125-5C4B6290-C291-4BF7-B594-5AB9A44D2F88Q38281851-8ADFBDCA-E4AA-469E-84A9-D4A9EA381F1EQ38513534-5F37C230-6852-4394-8BB6-EAD7FCE42B09Q38617612-84721EFE-0AC9-4D3D-92F5-1C23EABC9D41Q39865680-43A61A97-2E7A-44F3-830F-8B36BC727AFEQ40128190-E9B8B73B-F7A0-4639-9477-E3BB4C2F5D81Q40359341-4DE11A54-B976-40F3-AA3E-DE52138470DFQ41442242-24F785D1-283B-43BE-8E83-A0FAA0798353Q41661692-65471298-FC1F-4A47-A9D6-28C807219A07Q42100736-76DDD58F-A559-4C55-A002-819EF16EA6CBQ42199245-79B99D90-6990-4040-AC1C-6FC0C2E2C1FEQ42226854-7D522FAC-2CFE-4D3B-9D75-5DC52A9B7A03Q43497610-EEBA705D-51B8-47B0-9B6B-26E76941C2E9Q48103108-0B4B65EF-039F-4D25-B1FC-436FEC593D68Q52564628-452CA27E-33E9-4687-AD14-A17A57CC27C8Q52653110-41BE0631-96BE-4A78-B2BE-0034F3D38D84Q53038103-708084D1-99A1-4FAE-89AC-D79F63631ED2
P2860
Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh-hant
name
Reduced risk of recurrent leuk ...... ter cytomegalovirus infection.
@en
Reduced risk of recurrent leuk ...... ter cytomegalovirus infection.
@nl
type
label
Reduced risk of recurrent leuk ...... ter cytomegalovirus infection.
@en
Reduced risk of recurrent leuk ...... ter cytomegalovirus infection.
@nl
prefLabel
Reduced risk of recurrent leuk ...... ter cytomegalovirus infection.
@en
Reduced risk of recurrent leuk ...... ter cytomegalovirus infection.
@nl
P2093
P2860
P1476
Reduced risk of recurrent leuk ...... ter cytomegalovirus infection.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2141.1986.TB07551.X
P407
P50
P577
1986-08-01T00:00:00Z